Clariane SE (CLARI) fair value: what the stock is really worth
As of Oct 28, 2026: fair value (intrinsic value) of Clariane SE stock €3.65, price €3.25, upside +12.3%, quality 43 out of 100. Rating: undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Oct 28, 2026.
How to read this chart
60‑month range €0.8612 – €18.93 · fair‑value band €2.48 – €5.23 · the €3.25 price screens below the €3.65 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Oct 28, 2026.
Follow Clariane in your weekly email
Every Wednesday you see whether Clariane is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Clariane SE provides care homes, healthcare facilities and services, and shared living solutions in France, Germany, Benelux, Italy, Spain, and the United Kingdom. It operates long-term care and short stay nursing homes.
Show moreShow less
The company also provides inpatient and outpatient services, full-time hospitalization, day hospitalization, and outpatient care, and operates post-acute and rehabilitation care clinics, mental healthcare clinics, and medicine-surgery-obstetrics facilities.
In addition, it offers medicalized nursing homes and alternative living solutions, such as shared houses, assisted living, and domiciliary care, as well as outpatient consultations and diagnostics, and social care services.
The company was formerly known as Korian and changed its name to Clariane SE in June 2023. Clariane SE was founded in 2001 and is headquartered in Paris, France.
Stock analysis
Clariane SE (CLARI) currently trades at €3.25, while our model-based Fair Value estimate is €3.65, implying the stock looks roughly 11.0% undervalued today.
Show more
Valuation
Bull case: the Asset-Based group reads highest at a median of €4.22 per share, and 8 of the 23 models we run sit above the €3.25 price.
Bear case: the Dividend Discount group reads lowest at €0.4300, and 15 of the 23 models stay below the price. Data coverage for this calculation is high.
Scenario range: €2.48 (bear) to €5.23 (bull), the price of €3.25 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 43/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Clariane SE reported revenue of €5.3B in FY2025 versus €4.1B in FY2021, a compound +6.4%/yr. Reported net income was €1.6M in FY2025, compounding −63.6%/yr from FY2021.
Key figures
Market cap €1.2B Small · P/E ratio 108.3 · P/S ratio 0.22 · EPS (TTM) €0.0300 · Dividend yield 6.2% · Net margin 0.2% · Return on equity 0.7% · Return on assets (EBIT) 1.9%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 25 out of 100 (low confidence).
What moves the price
The share trades about 25% below its 52-week high and 5% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 19% fair-value upside, at 12%, CLARI screens richer than that median.
Fair Value models
Bear€2.48Fair Value €3.65Bull€5.23
Price €3.25 · Upside +12.3%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (€0.0248 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.74/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+0.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.1%
Start year 2020 (pandemic). Over 10 years: +7.5% a year
Revenue growth 21 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+18.1%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−57.8%
Earnings growth per share plus dividend.
Earnings per share, growth per year−64.0%
Dividend (yield on the price)6.2%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−64.0% vs −39.7%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.7% → 6%
Pace: the 5-year rate starts in 2020 (pandemic)
⚠ Revenue per share shrinking 2.6%/yr over ~10Y (margins eroding too) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far and less than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−14.1%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+3.2%
Yearly sales growth analysts expect, extended to five years.
After inflation (euro area: IMF forecast 2.2% a year to 2030, 2.6% from 2016 to 2025) that is about −15.9% a year for the price and +1.0% for the forecasts.
News mood ⓘNews mood, the average tone of recent news (57 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Positive
Recent news coverage is more positive than average.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 243 stocks
Beats the industry median on 5/14 measures
Overall it trails its industry peers.
Valuation
Quality Score43 · Bottom 25%
Fair Value upside+12.3% · Above median
Profitability
Return on equity (12 months)0.7% · Bottom 25%
Return on assets0.1% · Bottom 25%
Net margin (12 months)1.4% · Bottom 25%
Operating margin (12 months)5.8% · Below median
Growth and dividend
Revenue growth (quarter YoY)1.6% · Below median
Dividend yield (12 months)6.2% · Top 25%
Balance sheet
Debt / equity0.50× · Above median
Valuation Multiplesvs Medical Care Facilities median · lower = cheaper
P/E (12 months)108.3× · Priciest 25%
P/B0.36× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Clariane SE Fair Value". https://www.fairvalue-calculator.com/stock/CLARI
Frequently asked questions
Is Clariane SE (CLARI) overvalued or undervalued?
As of Oct 28, 2026, our model estimates a fair value of €3.65 versus a price of €3.25, about +12% upside (undervalued).
What is the fair value of CLARI?
Our model-based fair value for Clariane SE is €3.65 (as of Oct 28, 2026), built from audited fundamentals. The current price: €3.25.
What is the quality score of CLARI?
Clariane SE has a Quality Score of 43/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Clariane SE (CLARI)?
Our model-based price target is the fair value of €3.65 (as of Oct 28, 2026) from 23 valuation models. Cautious scenario €2.48, optimistic scenario €5.23. It is a calculation from audited fundamentals, not an analyst target.
What is the Clariane SE stock forecast for 2026?
Our models put fair value at €3.65, about +12% upside versus a price of €3.25 (undervalued). Cautious scenario €2.48, optimistic scenario €5.23. The calculation is refreshed regularly with new filings.
What is the revenue of Clariane SE (CLARI)?
Clariane SE reported trailing-twelve-month revenue of about €5.4B (latest available figure, as of Oct 28, 2026).
Does Clariane SE pay a dividend?
Clariane SE currently shows a dividend yield of 6.22% relative to its recent price (as of Oct 28, 2026).
What growth is priced into Clariane SE (CLARI)?
For today's price to be fair in a discounted-cash-flow model, Clariane SE would have to grow free cash flow by -14.1 % per year for five years (discount rate 11.2 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +7.1 % per year. As of Oct 28, 2026.
What discount rate (WACC) does the fair value of CLARI use?
Our models discount Clariane SE at 11.2 %: a base by market capitalisation (small), damped by beta 0.81, country premium for France. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Clariane SE that is -14.1 % per year a year over ten years, using the same discount rate (11.2 %) and the same formula as our fair value.
How much growth has Clariane SE (CLARI) delivered so far?
Over the past 5 years revenue at Clariane SE grew +7.1 % a year. The price currently implies -14.1 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Clariane SE (CLARI) growing?
The median revenue growth in the sector is +6.1 % a year. That is the yardstick for the growth priced into Clariane SE (-14.1 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Clariane SE (CLARI)?
The free-cash-flow yield on the price is 49.70 %: that much free cash flow Clariane SE produces per unit of market value. When it exceeds the discount rate of our models (11.2 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Clariane SE (CLARI)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Clariane SE it is €3.65 per share (as of Oct 28, 2026), against a price of €3.25. It is the blended result of 23 valuation models (cash flow, earnings, asset, dividend).
Is Clariane SE stock overvalued or undervalued in 2026?
As of Oct 28, 2026, CLARI trades below its calculated fair value: price €3.25, fair value €3.65, a gap of about +12% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CLARI?
No. The price is what the market pays today (€3.25); the fair value is what the company's own numbers justify (€3.65). For Clariane SE the two are €0.4000 per share apart. That gap is exactly why we show both numbers side by side.
How much is Clariane SE worth?
The market values Clariane SE at about €1.2B (market capitalisation, as of Oct 28, 2026). Per share that is €3.25; our models calculate a fair value of €3.65 per share.
What do the bullish and bearish scenarios say about CLARI?
Our models span a range for Clariane SE: cautious scenario €2.48, base €3.65, optimistic €5.23 per share (as of Oct 28, 2026, price €3.25). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of CLARI?
Clariane SE trades at a price-to-earnings ratio of 108.3 (as of Oct 28, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of €3.65 is built from several models across several years. Excluding one-off items of fiscal year 2025 it is 32.3 (reported for FY2025: 722.2). Median P/E at fiscal year-end, 8 fiscal years (2016 to 2025), reported earnings, FY2025 ex one-offs: 36.3. Other multiples: PEG 0.8, P/B 0.4, P/S 1.4, EV/EBITDA 20.8.
What is the PEG ratio of CLARI?
The PEG ratio of Clariane SE is 0.78 (P/E divided by earnings growth, as of Oct 28, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of Clariane SE (CLARI)?
Balance-sheet figures for Clariane SE (as of Oct 28, 2026): return on equity 0.7%, debt of 0.50 per unit of equity. They feed the Quality Score of 43/100, which measures business quality independently of the share price.
How far is CLARI from its 52-week high?
Clariane SE trades at €3.25, about 25% below its 52-week high of €4.35 and 5% above the low of €3.11 (as of Oct 28, 2026). Distance from the high says nothing about value: that is what the fair value of €3.65 is for.
Which stocks are comparable to Clariane SE?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Tenet Healthcare Corporation, Dr. Sulaiman Al Habib Medical Services Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Clariane SE stock attractive at the current price?
The data as of Oct 28, 2026: price €3.25, calculated fair value €3.65 (+12%), Quality Score 43/100, from 23 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CLARI calculated?
We run Clariane SE through 23 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of €3.65, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.4 % above its aggregate fair value. Clariane SE currently trades 11 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Clariane SE (CLARI)?
The closing price on Oct 28, 2026 was €3.25. Our model-based fair value is €3.65, about +12% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Clariane SE right now?
A fairly wide model range (€2.48 to €5.23) leaves room in how you read the outcome. The price sits in the lower half of our model range, the side with the larger margin of safety. The data supports the verdict: every model runs on fully documented inputs.
Key figures of Clariane SE
How large is the market capitalisation of Clariane SE (CLARI)?
The market capitalisation of Clariane SE is €1.2B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Clariane SE (CLARI)?
The price-to-sales ratio of Clariane SE is 0.22 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Clariane SE (CLARI)?
Earnings per share at Clariane SE are €0.0300 (price ÷ EPS = P/E 108.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Clariane SE (CLARI)?
The dividend yield of Clariane SE is 6.2%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Clariane SE (CLARI)?
The net margin of Clariane SE is 0.2% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Clariane SE (CLARI)?
The return on equity (ROE) of Clariane SE is 0.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Clariane SE (CLARI)?
On an EBIT basis the return on assets of Clariane SE is 1.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Clariane SE (CLARI)?
The operating margin of Clariane SE is 5.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Clariane SE (CLARI)?
Revenue at Clariane SE is growing +1.6% versus a year earlier (3y avg +6.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much net debt does Clariane SE (CLARI) carry?
The net debt of Clariane SE is €10.6B (fiscal year 2025, ≈ 18.3 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Clariane SE in the live analysis
One click puts Clariane SE on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.
Broad data
Oct 28, 2026